Bio-Techne Corporation TE1.F Stock
Bio-Techne Corporation Price Chart
Bio-Techne Corporation TE1.F Financial and Trading Overview
Bio-Techne Corporation stock price | 64 EUR |
Previous Close | 69.5 EUR |
Open | 69.5 EUR |
Bid | 69 EUR x N/A |
Ask | 77 EUR x N/A |
Day's Range | 69.5 - 69.5 EUR |
52 Week Range | 65.5 - 94.5 EUR |
Volume | 60 EUR |
Avg. Volume | 0 EUR |
Market Cap | 11.08B EUR |
Beta (5Y Monthly) | 1.256338 |
PE Ratio (TTM) | 46.02649 |
EPS (TTM) | 1.29 EUR |
Forward Dividend & Yield | 0.3 (0.41%) |
Ex-Dividend Date | May 12, 2023 |
1y Target Est | 549.6 EUR |
TE1.F Valuation Measures
Enterprise Value | 11.1B EUR |
Trailing P/E | 46.02649 |
Forward P/E | 7.713651 |
PEG Ratio (5 yr expected) | 4.22 |
Price/Sales (ttm) | 9.865498 |
Price/Book (mrq) | 5.7868443 |
Enterprise Value/Revenue | 9.88 |
Enterprise Value/EBITDA | 32.244 |
Trading Information
Bio-Techne Corporation Stock Price History
Beta (5Y Monthly) | 1.256338 |
52-Week Change | -9.86% |
S&P500 52-Week Change | 20.43% |
52 Week High | 94.5 EUR |
52 Week Low | 65.5 EUR |
50-Day Moving Average | 73.5 EUR |
200-Day Moving Average | 74.55 EUR |
TE1.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 157.44M |
Float | 155.97M |
Short Ratio | N/A |
% Held by Insiders | 0.89% |
% Held by Institutions | 96.50% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0.32 |
Trailing Annual Dividend Yield | 0.46% |
5 Year Average Dividend Yield | 49.00% |
Payout Ratio | 0.1908 |
Last Split Factor | 4:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | 24.14% |
Operating Margin (ttm) | 24.80% |
Gross Margin | 68.16% |
EBITDA Margin | 30.64% |
Management Effectiveness
Return on Assets (ttm) | 7.11% |
Return on Equity (ttm) | 15.09% |
Income Statement
Revenue (ttm) | 1.12B EUR |
Revenue Per Share (ttm) | 7.16 EUR |
Quarterly Revenue Growth (yoy) | 1.30% |
Gross Profit (ttm) | 758.09M EUR |
EBITDA | 344.29M EUR |
Net Income Avi to Common (ttm) | 271.22M EUR |
Diluted EPS (ttm) | 1.51 |
Quarterly Earnings Growth (yoy) | 15.59% |
Balance Sheet
Total Cash (mrq) | 157.2M EUR |
Total Cash Per Share (mrq) | 1 EUR |
Total Debt (mrq) | 473.99M EUR |
Total Debt/Equity (mrq) | 25.08 EUR |
Current Ratio (mrq) | 4.045 |
Book Value Per Share (mrq) | 12.01 |
Cash Flow Statement
Operating Cash Flow (ttm) | 273.72M EUR |
Levered Free Cash Flow (ttm) | 225.2M EUR |
Profile of Bio-Techne Corporation
Country | Germany |
State | MN |
City | Minneapolis |
Address | 614 McKinley Place N.E. |
ZIP | 55413 |
Phone | 612 379 8854 |
Website | https://www.bio-techne.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 3000 |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It has strategic partnership with Lunaphore Technologies S.A. to develop automated same-slide spatial multiomics solution. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Q&A For Bio-Techne Corporation Stock
What is a current TE1.F stock price?
Bio-Techne Corporation TE1.F stock price today per share is 64 EUR.
How to purchase Bio-Techne Corporation stock?
You can buy TE1.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Bio-Techne Corporation?
The stock symbol or ticker of Bio-Techne Corporation is TE1.F.
Which industry does the Bio-Techne Corporation company belong to?
The Bio-Techne Corporation industry is Biotechnology.
How many shares does Bio-Techne Corporation have in circulation?
The max supply of Bio-Techne Corporation shares is 157.19M.
What is Bio-Techne Corporation Price to Earnings Ratio (PE Ratio)?
Bio-Techne Corporation PE Ratio is 49.61240400 now.
What was Bio-Techne Corporation earnings per share over the trailing 12 months (TTM)?
Bio-Techne Corporation EPS is 1.29 EUR over the trailing 12 months.
Which sector does the Bio-Techne Corporation company belong to?
The Bio-Techne Corporation sector is Healthcare.